Webcast and event slides available
here
OmniAb, Inc. (Nasdaq: OABI) held its first Research &
Technology virtual event earlier today, during which members of the
management team reviewed the Company’s technology offerings and
highlighted the launch of OmnidAb, the industry’s first and only
transgenic chicken producing single domain antibodies (sdAbs). The
archived webcast and speaker slides will be available on the
Investors portion of OmniAb’s website.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231109832856/en/
(Photo: Business Wire)
“Since the completion of the transaction that created OmniAb as
an independent public company almost exactly one year ago, we’ve
made tremendous progress in building out our business and research
teams and increasing the number of active partner programs. With
the infrastructure in place to support our highly scalable business
model, OmniAb is well positioned for significant growth with a
differentiated platform as we facilitate the discovery and
development of novel therapeutic antibodies by our partners,” said
Matt Foehr, Chief Executive Officer of OmniAb.
“Our technologies are making important impacts on our partners’
R&D pipelines and are having positive impacts on patients’
lives. OmnidAb is an exciting new technology that is now being used
by our partners. We look forward to additional new technologies and
partner experience enhancements launching next year and beyond as
our internal innovation engine is becoming more efficient,” he
added.
Today’s virtual event featured presentations from senior
management with business updates and an overview of various
technology platforms, including the newly-launched OmnidAb
platform.
“We continue to innovate around our technology offerings. The
latest innovation is OmnidAb, a platform for single domain
antibodies based upon a human VH scaffold that affinity matures in
a chicken host environment to provide a functionally diverse immune
repertoire unavailable from mammalian systems. OmnidAb is the first
and only transgenic chicken producing sdAbs and creates the
opportunity to significantly improve discovery approaches at a time
when there is growing industry interest in the modality,” said Bill
Harriman, Ph.D., Senior Vice President, Antibody Discovery of
OmniAb.
OmnidAb™ Technology Launch
Management provided an overview of the OmnidAb transgenic
chicken novel host system that builds upon the success of its
OmniChicken legacy. Highlights included:
- OmnidAb transgenic chickens express an optimized single-domain
humanized framework, which can be utilized as modular building
blocks, unlocking the versatility to “fit the biology” for a wide
range of human disease, and are well suited to support a variety of
therapeutic modalities.
- OmnidAb antibodies target distinct epitopes and have favorable
developability profiles with high expression levels in mammalian
cells.
- The current predominant process to discover therapeutic sdAbs
requires large animal immunization and engineering – including
humanization and optimization – adding time and increasing risks.
Built-in use of an optimized human scaffold combined with efficient
in vivo affinity maturation in OmnidAb minimizes the need for
downstream engineering.
- Distinct from traditional antibodies, sdAbs produced by OmnidAb
chickens have a compact format that opens significant new
opportunities. Given their unique physical properties, they can be
leveraged for alternate routes of administration, diagnostic
applications and therapeutic approaches beyond what is typically
possible with conventional antibodies.
Enhancing Discovery with OmniDeep™
Management also discussed the ability to enhance discovery
capabilities with OmniDeep, a suite of in silico tools for
therapeutic discovery and optimization that is woven through
OmniAb’s various technologies. Building upon the Biological
Intelligence™ (BI) embedded within the diverse antibody repertoires
from OmniAb animals, OmniDeep leverages artificial intelligence
(AI) and machine learning to assist antibody discovery and
optimization. The combination of BI and AI offers partners new
large-scale discovery workflows and optimization tools for their
discovery campaigns.
The Ion Channel Opportunity
Lastly, management highlighted differentiated core capabilities
to target ion channels and transporters, as they are key components
in various biological processes.
OmniAb’s ion channel technologies, coupled with its experienced
team of ion drug discovery experts, offers a differentiated
capability to advance the discovery of this class of therapeutics.
The company has key collaborations for these high-value targets
with GSK and Roche. OmniAb differentiates its ion channel discovery
platform via continuous expansion and development of cutting-edge
technologies, including custom cell lines, high-throughput
electrophysiology, proprietary X-ray fluorescence, structure-based
optimization leveraging cryo-EM and molecular dynamics, deep
learning models and more. Because key areas for ion channels are
buried in the membrane and can be challenging to reach, the smaller
size of OmnidAb and OmniTaur™ binding domains compared to
conventional antibodies provides a new approach to ion channel
therapeutics.
About OmniAb®
OmniAb’s discovery platform provides pharmaceutical industry
partners access to diverse antibody repertoires and high-throughput
screening technologies to enable discovery of next-generation
therapeutics. At the heart of the OmniAb platform is the Biological
Intelligence™ (BI) of our proprietary transgenic animals, including
OmniRat®, OmniChicken® and OmniMouse® that have been genetically
modified to generate antibodies with human sequences to facilitate
development of human therapeutic candidates. OmniFlic® (transgenic
rat) and OmniClic® (transgenic chicken) address industry needs for
bispecific antibody applications through a common light chain
approach, and OmniTaur™ features unique structural attributes of
cow antibodies for complex targets. OmnidAb™ is an in vivo platform
for single domain antibodies based upon a human VH scaffold that
affinity matures in a chicken host environment to provide a
functionally diverse immune repertoire unavailable from mammalian
systems. We believe the OmniAb animals comprise the most diverse
host systems available in the industry and they are optimally
leveraged through computational antigen design and immunization
methods, paired with high-throughput single B cell phenotypic
screening and mining of next-generation sequencing datasets with
custom algorithms to identify fully human antibodies with superior
performance and developability characteristics. These proprietary
technologies are joined with and leverage OmniDeep™, which is a
suite of in silico tools for therapeutic discovery and optimization
that are woven throughout OmniAb’s various technologies and
capabilities. Additionally, an established core competency focused
on ion channels and transporters further differentiates OmniAb’s
technology and creates opportunities in many emerging target
classes. OmniAb antibodies have been leveraged across modalities,
including bispecific antibodies, antibody-drug conjugates and
others.
The OmniAb suite of technologies span from BI-powered repertoire
generation to cutting-edge antibody discovery and optimization
offering a highly efficient and customizable end-to-end solution
for the growing discovery needs of the global pharmaceutical
industry.
For more information, please visit www.omniab.com.
Forward-Looking Statements
OmniAb cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. Words such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “intend,” “target,”
“project,” “contemplates,” “believes,” “estimates,” “predicts,”
“potential” or continue” and similar expressions, are intended to
identify forward-looking statements. The forward-looking statements
are based on our current beliefs and expectations and include, but
are not limited to: the growth prospects of our business and the
discovery needs of the pharmaceutical industry; the scalability of
our business model based on our current infrastructure; the
expected launch and performance of, our technologies and partner
experience enhancements and the opportunities they may create; and
the ability to add new partners and programs. Actual results may
differ from those set forth in this press release due to the risks
and uncertainties inherent in our business, including, without
limitation: our future success is dependent on acceptance of our
technology platform and technologies by new and existing partners,
as well as on the eventual development, approval and
commercialization of products developed by our partners for which
we have no control over the development plan, regulatory strategy
or commercialization efforts; biopharmaceutical development is
inherently uncertain; risks arising from changes in technology; the
competitive environment in the life sciences and biotechnology
platform market; our failure to maintain, protect and defend our
intellectual property rights; difficulties with performance of
third parties we will rely on for our business; regulatory
developments in the United States and foreign countries; unstable
market and economic conditions, may have serious adverse
consequences on our business, financial condition and stock price;
and other risks described in our prior press releases and filings
with the SEC, including under the heading “Risk Factors” in our
annual report on Form 10-K and any subsequent filings with the SEC.
You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and we undertake no obligation to update such statements to reflect
events that occur or circumstances that exist after the date
hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, which is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231109832856/en/
OmniAb, Inc. Neha Singh, Ph.D. investors@OmniAb.com X (Twitter)
@OmniAbTech (510) 768-7760
OmniAb (NASDAQ:OABI)
Historical Stock Chart
From Sep 2024 to Oct 2024
OmniAb (NASDAQ:OABI)
Historical Stock Chart
From Oct 2023 to Oct 2024